CN106687113B - ω-3组合物、剂型及使用方法 - Google Patents

ω-3组合物、剂型及使用方法 Download PDF

Info

Publication number
CN106687113B
CN106687113B CN201580030195.7A CN201580030195A CN106687113B CN 106687113 B CN106687113 B CN 106687113B CN 201580030195 A CN201580030195 A CN 201580030195A CN 106687113 B CN106687113 B CN 106687113B
Authority
CN
China
Prior art keywords
dosage form
oil
fatty acid
esterified
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580030195.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN106687113A (zh
Inventor
欧拉夫·桑德内斯
布鲁斯·A·米勒
卓恩·戴伯格
史提恩·史坦德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marine Ingredients LLC
Original Assignee
Marine Ingredients LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marine Ingredients LLC filed Critical Marine Ingredients LLC
Publication of CN106687113A publication Critical patent/CN106687113A/zh
Application granted granted Critical
Publication of CN106687113B publication Critical patent/CN106687113B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN201580030195.7A 2014-06-06 2015-06-05 ω-3组合物、剂型及使用方法 Active CN106687113B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462009145P 2014-06-06 2014-06-06
US62/009,145 2014-06-06
US201462019289P 2014-06-30 2014-06-30
US62/019,289 2014-06-30
PCT/US2015/034372 WO2015188046A1 (en) 2014-06-06 2015-06-05 Omega-3 compositions, dosage forms, and methods of use

Publications (2)

Publication Number Publication Date
CN106687113A CN106687113A (zh) 2017-05-17
CN106687113B true CN106687113B (zh) 2021-09-03

Family

ID=54767418

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580030195.7A Active CN106687113B (zh) 2014-06-06 2015-06-05 ω-3组合物、剂型及使用方法

Country Status (14)

Country Link
US (4) US9675575B2 (enExample)
EP (2) EP3906920A1 (enExample)
JP (2) JP6755186B2 (enExample)
KR (1) KR102400958B1 (enExample)
CN (1) CN106687113B (enExample)
AU (1) AU2015269307C1 (enExample)
BR (1) BR112016028561A8 (enExample)
CA (1) CA2950344C (enExample)
CL (1) CL2016003131A1 (enExample)
MX (1) MX2016015791A (enExample)
MY (1) MY186566A (enExample)
RU (1) RU2741965C2 (enExample)
TW (1) TWI725937B (enExample)
WO (1) WO2015188046A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10709680B2 (en) * 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
CN106687113B (zh) * 2014-06-06 2021-09-03 海洋原料公司 ω-3组合物、剂型及使用方法
CN110958731A (zh) 2018-09-21 2020-04-03 鸿盛国际有限公司 发光二极管并联电路
FR3103355B1 (fr) 2019-11-26 2024-05-31 Polaris Composition d’huile de micro-organismes enrichie en acides gras polyinsaturés
FR3151183A1 (fr) 2023-07-20 2025-01-24 Microphyt Nouvelle utilisation d’un extrait de la microalgue Phaeodactylum tricornutum

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
FR2731015B1 (fr) 1995-02-24 1997-05-30 Sci Sartone Procede d'enrichissement enzymatique d'huiles d'origine marine et les triglycerides d'acides gras polyinsatures ainsi obtenus
JP2000501131A (ja) * 1995-11-24 2000-02-02 ロダース・クロックラーン・ビー・ブイ 魚油をベースとする組成物
US7799365B2 (en) * 2001-04-06 2010-09-21 Burnbrae Farms Limited Liquid egg composition including fish oil with omega-3 fatty acid
US7169385B2 (en) 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
SE0303513D0 (sv) 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
US20070020340A1 (en) * 2005-07-25 2007-01-25 David Rubin Fish oil products for reducing cholesterol, low density lipoprotein, and hypertension
US20090182050A1 (en) 2005-10-07 2009-07-16 Ocean Nutrition Canada, Ltd. Salts of Fatty Acids and Methods of Making and Using thereof
CA2634139C (en) 2005-12-20 2015-06-23 Cenestra, Llc. Omega 3 fatty acid formulations
US9265745B2 (en) 2005-12-21 2016-02-23 Brudy Technology S.L. Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage
CA2655769A1 (en) 2006-06-23 2007-12-27 The Procter & Gamble Company Concentrated omega-3 fatty acids and mixtures containing them
WO2008036353A2 (en) 2006-09-19 2008-03-27 The Trustees Of Columbia University In The City Of New York Omega-3 diglyceride emulsions
EP2147088A4 (en) * 2007-04-26 2010-05-05 Patrick Adlercreutz FERTILIZED MILK OILS COMPRISING MULTIPLE-UNSATURATED FATTY ACIDS, COMPRISING EICOSAPENTAIC ACID (EPA) AND DOCOSAHEXAIC ACID (DHA), AND MANUFACTURING METHOD THEREFOR
US20100119600A1 (en) 2007-06-01 2010-05-13 Joar Opheim Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
CL2008002020A1 (es) 2007-07-12 2008-11-14 Ocean Nutrition Canada Ltd Metodo de modificacion de un aceite, que comprende hidrolizar gliceridos con una solucion de lipasa thermomyces lanuginosus, separar la fraccion de acido graso saturado de la fraccion de glicerido hidrolizado y esterificar los gliceridos hidrolizados en la presencia de candida antarctica lipasa b; y composicion de aceite.
WO2009017102A1 (ja) * 2007-07-30 2009-02-05 Nippon Suisan Kaisha, Ltd. Epa濃縮油およびdha濃縮油の製造方法
KR101045397B1 (ko) 2008-07-04 2011-06-30 주식회사동우산업 오메가-3 지방산 함량이 높은 정제 오징어유의 제조방법
GB0813599D0 (en) 2008-07-24 2008-09-03 Pharma Marine As Method
RS53694B1 (sr) * 2008-08-07 2015-04-30 Spa Societa' Prodotti Antibiotici S.P.A. Dugoročno lečenje simptomatske srčane insuficijencije
US20100236137A1 (en) * 2008-09-23 2010-09-23 LiveFuels, Inc. Systems and methods for producing eicosapentaenoic acid and docosahexaenoic acid from algae
AU2010222648B2 (en) * 2009-03-09 2016-07-07 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
CN101695487B (zh) * 2009-09-22 2012-01-18 北京百慧生化制药有限责任公司 一种高纯度epa-e、dha-e的多烯酸乙酯乳剂
FR2955459B1 (fr) 2010-01-28 2013-11-22 Polaris Composition huileuse riche en monoglycerides de dha
US20110223246A1 (en) * 2010-03-10 2011-09-15 Joar Opheim Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source
WO2011133841A2 (en) 2010-04-23 2011-10-27 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Intravenous omega-3 fatty acid compositions & method of use
KR101904392B1 (ko) * 2010-09-24 2018-10-05 프로노바 바이오파마 너지 에이에스 오메가-3 지방산을 농축하기 위한 공정
US20120252888A1 (en) * 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders
AU2012347606A1 (en) * 2011-12-08 2014-06-26 Metaproteomics, Llc Supplemented oil compositions and methods for improved health
WO2013093630A2 (en) * 2011-12-22 2013-06-27 Pronova Biopharma Norge As Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof
CN110478342A (zh) 2012-05-10 2019-11-22 索卢泰克斯Na有限责任公司 含有天然专门促消退介质及其前体的具有抗炎活性的油
EP3756658A1 (en) 2012-09-24 2020-12-30 Aker Biomarine Antarctic As Omega -3 compositions
US20130310457A1 (en) 2013-07-25 2013-11-21 Niral Ramesh Solid-in-oil dispersions
CN106687113B (zh) * 2014-06-06 2021-09-03 海洋原料公司 ω-3组合物、剂型及使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioavailability of marine n-3 fatty acid formulations;J. Dyerberg;《Prostaglandins, Leukotrienes and Essential Fatty Acids》;20101231;137-141 *

Also Published As

Publication number Publication date
AU2015269307A1 (en) 2017-01-05
RU2016149416A (ru) 2018-07-10
BR112016028561A2 (pt) 2017-08-22
RU2741965C2 (ru) 2021-02-01
US20210308086A1 (en) 2021-10-07
AU2015269307C1 (en) 2019-10-03
RU2016149416A3 (enExample) 2018-12-05
US20160243068A1 (en) 2016-08-25
KR20170018825A (ko) 2017-02-20
US9675575B2 (en) 2017-06-13
CA2950344A1 (en) 2015-12-10
US20180303784A1 (en) 2018-10-25
WO2015188046A1 (en) 2015-12-10
AU2015269307B2 (en) 2019-03-14
TW201613571A (en) 2016-04-16
EP3151826A4 (en) 2018-01-24
US11160777B2 (en) 2021-11-02
JP6755186B2 (ja) 2020-09-16
CN106687113A (zh) 2017-05-17
CA2950344C (en) 2023-09-19
EP3151826A1 (en) 2017-04-12
EP3906920A1 (en) 2021-11-10
US20170252313A1 (en) 2017-09-07
MY186566A (en) 2021-07-27
US10172819B2 (en) 2019-01-08
BR112016028561A8 (pt) 2021-06-29
TWI725937B (zh) 2021-05-01
US10034849B2 (en) 2018-07-31
JP2020105224A (ja) 2020-07-09
KR102400958B1 (ko) 2022-05-20
CL2016003131A1 (es) 2017-06-09
JP2017516811A (ja) 2017-06-22
MX2016015791A (es) 2017-05-30

Similar Documents

Publication Publication Date Title
US11160777B2 (en) Omega-3 compositions, dosage forms, and methods of use
RU2276975C2 (ru) Терапевтические комбинации жирных кислот
Calviello et al. Low-dose eicosapentaenoic or docosahexaenoic acid administration modifies fatty acid composition and does not affect susceptibility to oxidative stress in rat erythrocytes and tissues
Guo et al. Camellia oil lowering blood pressure in spontaneously hypertension rats
JPH02104522A (ja) 脂肪酸を含有する医薬用組成物
Danbara et al. Conjugated docosahexaenoic acid is a potent inducer of cell cycle arrest and apoptosis and inhibits growth of colo 201 human colon cancer cells
JP6387371B2 (ja) メタボリックシンドローム改善剤
JPH04290822A (ja) アレルギー予防薬および食品
JP2001247473A (ja) インスリン抵抗性改善剤
JP2020182497A (ja) 一価不飽和脂肪酸組成物およびアテローム性動脈硬化症を処置するための使用
EP3558292A1 (en) Omega-3 fatty acid composition for preventing and/or treating cachexia
WO2024043787A1 (en) Cetoleic acid composition
JPS6293234A (ja) 精製された魚油およびその製造方法
HK1238139A1 (en) Monounsaturated fatty acid compositions and use for treating atherosclerosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant